Immunotherapy for Infectious Diseases

214 Jacobson
22. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for
prevention of perinatal transmission of hepatitis B virus carrier state: final report of randomized
double-blind, placebo-controlled trial. Hepatology 1983; 3:135–141.
23. Krause RM, Dimmock NJ, Morens DM. Summary of antibody workshop: The Role of
Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious
Diseases. J Infect Dis 1997; 176:549–559.
24. Casedevall A. Crisis in infectious disease: time for a new paradigm? Clin Infect Dis 1996;
23:790–794.
25. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in
AIDS. Nat Med. 1998; 4:679–684.
26. Hairharan K, Nara PL, Caralli VM, Norton FL, Haigwood N, Kang CY. Analysis of the
cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected
asymptomatic individuals. J Virol 1993; 67:953–960.
27. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of
human immunodeficiency virus type 1. J Virol 1993; 67:6642–6647.
28. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion-competent
vaccines: broad neutralization of primary isolates of HIV. Science 1999; 283:357–362.
29. Matsushita S, Robert-Guroff M, Rusche J, et al. Characterization of a human immunodefiency
virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
J Virol 1998; 62:2107.
30. Moore JP, Nara PL. The role of the V3 loop in HIV infection. AIDS 1991; 5(Suppl 2):S21.
31. Rusche JR, Javaherian K, McDanal C, et al. Antibodies that inhibit fusion of human
immunodeficiency virus-infected cells bind a 24-amino-acid sequence of the viral envelope
gp120. Proc Natl Acad Sci USA 1988; 85:3198–3202.
32. Yamanaka T, Fujimura Y, Ishimoto S, et al. Correlation of titer of antibody to principal
neutralizing domain of HIV MN strain with disease progression in Japanese hemophiliacs
seropositive for HIV type 1. AIDS Res Hum Retroviruses 1997; 13:317.
33. Devash Y, Calvelli TA, Wood DG, Reagan KJ, and Rubinstein A.Vertical transmission of
HIV is correlated with the absence of high affinity/avidity maternal antibodies to the
gp120 principal neutralizing domain. Proc Natl Acad Sci USA 1990; 87:3445–3449.
34. Cocchi F, DeVico AL, Demo AG, Cara A, Gallo RC, Lusso P. V3 domain of HIV-1 envelope
glycoprotein gp120 is critical for chemokine-mediated blockade of infection. Nat
Med 1996; 2:1244.
35. Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees
by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355:728–730.
36. Girard M, Barre-Sinoussi F, van der Ryst E. Vaccination of chimpanzees against HIV-1.
Antibiot Chemother 1996; 48:121–124.
37. Gorny MK, Conley AJ, Karwowska S, et al. Neutralization of diverse HIV-1 variants by
an anti-V3 human monoclonial antibody. J Virol 1992; 66:7538–7542.
38. Jahaverian K, Langlois AJ, LaRosa FJ, et al. Broadly neutralizing antibodies elicited by
the hypervariable neutralizing determinant of HIV-1. Science 1990; 250:1590–1593.
39. Moore JP, Cao Y, Quing L, et al. Primary isolates of human immunodeficiency virus type
1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their
neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69:101.
40. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1
by a recombinant human monoclonal antibody. Science 1994; 266:1024–1027.
41. Posner MR, Cavacini LA, Emes CL, Power J, Byrn RA. Neutralization of HIV-1 by F105,
a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic
Syndr 1993; 6:7–14.
42. Fevrier M, Boudet F, Deslandres A, Theze J. Two new monoclonal antibodies against HIV
type 1 glycoprotein gp120: characterization and neutralizing activities against HIV type 1
strains. AIDS Res Hum Retroviruses 1995; 11:491–500.